Preoperative Preparation With Lugol Solution in Patients With Graves-Basedow Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-25

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, both the American Thyroid Association and the European Thyroid Association recommend the use of Lugol Solution (LS) in the preparation of patients undergoing thyroidectomy for Graves' disease (GD), but their recommendations are based on a low level of evidence. This means that its use is not generalized among the different endocrine surgery units.

Methods:

Study population: 270 patients (135 patients in each arms) undergoing total thyroidectomy (TT) due to GD in Spanish hospitals, which perform a minimum of 100 thyroidectomies a year, at least 10 of them for GD.

Variables:

Preoperative variables

* Demographic variables: birthdate, gender and ethnicity.
* Drugs allergies. Allergy to iodine.
* Personal history and usual treatment.
* Aspects related to the GD: date of diagnosis, use of AT drugs and/or radioiodine, existence of ophthalmopathy, existence of cervical compression symptoms and indication of surgery.
* Physical exploration: body mass index, pulse at rest and blood pressure and cervical palpation.
* Laboratory tests: hematocrit, leukocytes, neutrophils, platelets, international normalized ratio(INR), creatinine, potassium, total calcium, albumin, total proteins, parathormone (PTH), 25-hydroxide-vitamin D, free T4 and / or free T3, TSH, thyroid stimulating immunoglobulin (TSI).
* Classification of the anesthetic risk of ASA.
* Cervical ultrasound: existence of thyroid nodules and volume of the thyroid.
* Mobility of the vocal cords evaluated by laryngoscopy.
* Compliance with assigned treatment: the patient assigned to the LS arm must have consumed at least 80% of the total dose indicated.

Intraoperative variables

* Surgical time.
* Antibiotic prophylaxis
* Intraoperative hemorrhage.
* Thyroidectomy Difficulty Scale.
* Loss of electromyographic signal during neural intraoperative monitorization.
* Accidental parathyroidectomy.
* Section or obvious lesion of the recurrent laryngeal nerve.
* Trachea or esophagus perforation.
* Weight of the gland.
* Electrosurgical hemostasis system used during the intervention.
* Maneuvers used to check hemostasis.
* Hemostats used during the intervention.
* Use of drainage.
* Definitive surgical technique: TT, unilateral or bilateral subtotal thyroidectomy or hemithyroidectomy.

Postoperative variables

* Early complications: hypoparathyroidism, paralysis of the recurrent laryngeal nerve, postoperative hematoma, surgical site infection or death.
* Debit for surgical drains.
* Postoperative hospital long of stay.
* Anatomopathological variables: histological diagnosis compatible with GD and existence of parathyroid glands in the surgical specimen.
* Long-term complications: hypocalcemia and/or permanent vocal cord paralysis longer than 6 months

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter

NCT04856488

Hyperthyroidism

RECRUITING PHASE3

Preoperative Administration of Lugols Solution in Toxic Thyroid Diseases (TD): A Prospective Study

NCT06176976

Toxic; Thyroid

ACTIVE_NOT_RECRUITING NA

Effect of Lugol's Solution in the Patients With Graves' Disease

NCT00432146

Graves Disease

COMPLETED

Clinical and Surgical Outcomes of Total Thyroidectomy in Basedow's Disease: the Effect of Lugol Solution

NCT05784792

Basedow Disease

ENROLLING_BY_INVITATION NA

Thyroidectomy for Graves' Disease or Amiodarone-induced Thyrotoxicosis

NCT06963203

Graves Disease Amiodarone-Induced Thyrotoxicosis Thyroidectomy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperthyroidism, Autoimmune

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Preoperative Lugol Solution preparation

Patients will receive Lugol Solution preparation for 10 days before thyroidectomy

Group Type EXPERIMENTAL

Lugols Strong Iodine

Intervention Type DRUG

5 L.I. drops / 8 hours for 10 days before surgery

No preparation

Patients will not receive preparation before thyroidectomy

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lugols Strong Iodine

5 L.I. drops / 8 hours for 10 days before surgery

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who meet all of the following criteria will be eligible:

* The age of the patient must be over 18 years of age.
* The patient or his / her tutor, in cases where this is the case, has the capacity to understand the study and agrees to participate in it, by signing the corresponding informed consent document.
* Patients who have been diagnosed with GD, defined as the existence of hyperthyroidism (TSH \< lower limit of laboratory normality associated with TSI \> upper limit of laboratory normality) that present ultrasonographic data (diffuse vascularization increase) and / or scintigraphy (diffuse uptake of the radioisotope) compatible with GD.
* Euthyroid patients (free T4 and / or free T3 within the normal range of the laboratory) at the time of randomization, and under treatment with AT drugs (propylthiouracil, carbimazole or methimazole).
* The patient must be proposed for total thyroidectomy, using a transcervical approach.

Exclusion Criteria

The participant can not participate in the study if he / she presents any of the following circumstances:

* Prior cervicotomy by surgical intervention on the thyroid or parathyroid gland.
* Associated hyperparathyroidism that requires associating a parathyroidectomy in the same surgical act.
* Associated thyroid cancer that requires adding a lymph node dissection of the central or lateral compartment in the same surgical time.
* Iodine allergy.
* Consumption of lithium or amiodarone between randomization and administration of LS.
* Patients with category IV of the anesthetic risk classification of the American Society of Anesthesiologists (ASA).
* Women who breastfeed during the administration of the LS or in the month after it.
* Preoperative palsy of a vocal cord verified by laryngoscopy.
* Surgery performed by training specialists, or by staff not specifically dedicated to endocrine surgery.
* Surgery not performed under general anesthesia.
* Endoscopic surgery, video assisted or by remote approach.
* Surgery performed in out-patient settings.
* Current drug consumption or alcohol abuse that could interfere with meeting the study requirements.
* Participation in any other trial with medications in the month prior to randomization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No